EcoDrugPlus

Toll Like Receptor 7

Ensembl ID : ENSPKIG00000011740
Gene Symbol: TLR7
3 Cross references
197 Possible Orthologues:

Toll Like Receptor 8

Ensembl ID : ENSPKIG00000011748
Gene Symbol: TLR8
2 Cross references
187 Possible Orthologues:

Toll-Like Receptor 2

Ensembl ID : ENSPKIG00000009763
Gene Symbol: LOC111846509
2 Cross references
239 Possible Orthologues:

Toll-Like Receptor 2

Ensembl ID : ENSPKIG00000013599
Gene Symbol: LOC111836729
2 Cross references
249 Possible Orthologues:

Trace Amine-Associated Receptor 1-Like

Ensembl ID : ENSPKIG00000011320
Gene Symbol: LOC111836190
2 Cross references
146 Possible Orthologues:

Trace Amine-Associated Receptor 1-Like

Ensembl ID : ENSPKIG00000010514
Gene Symbol: LOC111852671
2 Cross references
146 Possible Orthologues:

Trace Amine-Associated Receptor 1-Like

Ensembl ID : ENSPKIG00000011305
Gene Symbol: LOC111836141
2 Cross references
146 Possible Orthologues:

Transient Receptor Potential Cation Channel Subfamily A Member 1

Ensembl ID : ENSPKIG00000006784
Gene Symbol: TRPA1
3 Cross references
133 Possible Orthologues:

Transient Receptor Potential Cation Channel, Subfamily A, Member 1a

Ensembl ID : ENSPKIG00000017898
Gene Symbol: TRPA1A
1 Cross references
155 Possible Orthologues:

Transthyretin

Ensembl ID : ENSPKIG00000003564
Gene Symbol: TTR
3 Cross references
178 Possible Orthologues:

Tryptophan 5-Hydroxylase 1-Like

Ensembl ID : ENSPKIG00000011601
Gene Symbol: LOC111835440
4 Cross references
148 Possible Orthologues:

Tryptophan Hydroxylase 1

Ensembl ID : ENSPKIG00000020326
Gene Symbol: TPH1
4 Cross references
192 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).